That's right. It was Hinrich's patent Interleukins IL-21 and IL-15 that bothered me, and their inflammatory deregulation effects in cancers. Obviously Interleukins being a major component of Remestemcel-L's anti inflammatory cascade....
Have to dust the cobwebs out on this stuff:
https://www.tga.gov.au/sites/default/files/auspar-remestemcel-l-150315.pdf
Anyway, as you guys importantly point out, all that EAP data very reasonably concluded as back in play from your and others excellent understanding of the FDA prcoedures and processes, that lead to that logical deduction. We should all be doing our research, but @stockrock and @imback yourself and others, thanks for the excellent insights - reminds me of a return to the good old days of MSB threads with some very well informed discussion. We waz robbed.
Mesoblast stock(rock)-take March 2024, page-187
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.050(4.39%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.17 | $1.07 | $8.385M | 7.489M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8500 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 26954 | 3 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |